Eben Tessari Sells 12,048 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari sold 12,048 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $41.56, for a total value of $500,714.88. Following the transaction, the chief operating officer directly owned 16,666 shares of the company’s stock, valued at approximately $692,638.96. The trade was a 41.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Eben Tessari also recently made the following trade(s):

• On Wednesday, November 26th, Eben Tessari sold 200 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $42.89, for a total value of $8,578.00.
• On Monday, November 17th, Eben Tessari sold 12,470 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.24, for a total value of $514,262.80.
• On Tuesday, October 14th, Eben Tessari sold 12,368 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $37.67, for a total value of $465,902.56.
• On Monday, September 29th, Eben Tessari sold 42,000 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $38.33, for a total value of $1,609,860.00.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA traded up $0.10 on Wednesday, reaching $41.47. The company’s stock had a trading volume of 389,886 shares, compared to its average volume of 600,411. Kiniksa Pharmaceuticals International, plc has a twelve month low of $17.82 and a twelve month high of $42.98. The stock has a market cap of $3.14 billion, a PE ratio of 92.16 and a beta of 0.02. The firm’s 50 day moving average is $39.97 and its two-hundred day moving average is $34.74.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The business had revenue of $180.86 million during the quarter, compared to analyst estimates of $166.64 million. During the same period in the prior year, the firm earned ($0.18) EPS. The business’s revenue for the quarter was up 61.2% on a year-over-year basis. Equities research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on KNSA. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. The Goldman Sachs Group lifted their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Citigroup boosted their target price on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Finally, Wells Fargo & Company lifted their price target on Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an “overweight” rating in a research note on Thursday, September 25th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.00.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds have recently modified their holdings of the business. Invesco Ltd. raised its position in Kiniksa Pharmaceuticals International by 137.4% during the first quarter. Invesco Ltd. now owns 33,492 shares of the company’s stock valued at $744,000 after buying an additional 19,384 shares during the period. Savant Capital LLC acquired a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth about $398,000. Vanguard Group Inc. grew its stake in Kiniksa Pharmaceuticals International by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock valued at $74,606,000 after acquiring an additional 151,604 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Kiniksa Pharmaceuticals International by 30.4% in the 1st quarter. Wellington Management Group LLP now owns 91,032 shares of the company’s stock valued at $2,022,000 after purchasing an additional 21,219 shares during the period. Finally, Acadian Asset Management LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 170.3% in the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock worth $22,961,000 after purchasing an additional 651,700 shares in the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.